Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study

MLA

Susumu Hijioka, et al. “Long‐term Safety and Efficacy of Lanreotide Autogel in Japanese Patients with Neuroendocrine Tumors: Final Results of a Phase II Open‐label Extension Study.” Asia-Pacific Journal of Clinical Oncology, vol. 17, Aug. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....06c1d076bdc592356176509d8df11cd0&authtype=sso&custid=ns315887.

APA

Susumu Hijioka, Akira Fukutomi, Atsushi Kudo, Akira Shimatsu, Yasutoshi Kimura, Tetsuhide Ito, Akihiro Nakajima, Shinji Katsushima, Seiichi Hisamatsu, Nao Fujimori, & Yoshitaka Honma. (2020). Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study. Asia-Pacific Journal of Clinical Oncology, 17.

Chicago

Susumu Hijioka, Akira Fukutomi, Atsushi Kudo, Akira Shimatsu, Yasutoshi Kimura, Tetsuhide Ito, Akihiro Nakajima, et al. 2020. “Long‐term Safety and Efficacy of Lanreotide Autogel in Japanese Patients with Neuroendocrine Tumors: Final Results of a Phase II Open‐label Extension Study.” Asia-Pacific Journal of Clinical Oncology 17 (August). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....06c1d076bdc592356176509d8df11cd0&authtype=sso&custid=ns315887.